evinacumab   Click here for help

GtoPdb Ligand ID: 8717

Synonyms: evinacumab-dgnb | Evkeeza® | REGN1500
Approved drug
evinacumab is an approved drug (FDA (2021))
Compound class: Antibody
Comment: Evinacumab is a fully human monoclonal antibody targeting angiopoietin-like 3 (ANGPTL3). Due to its role in lipid metabolism, ANGPTL3 is being investigated as a potential molecular target for the treatment of hypertriglyceridemia.
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record.
A BLAST search of patented peptide sequences reveals that the heavy chain variable domain of evinacumab is identical to SEQ ID: NO 66 from patent US9018356 B2 [3], and the light chain variable region is identical to SEQ ID: NO 74 from the same patent (this heavy/light chain combination corresponds to antibody identifier H4H1276S).

Evinacumab utilises a different molecular mechanism compared to Regeneron's already approved anti-hyperlipidemic drug alirocumab (targets proprotein convertase subtilisin/kexin type 9).
Classification Click here for help
Compound class Antibody
Approved drug? Yes (FDA (2021))
International Nonproprietary Names Click here for help
INN number INN
10013 evinacumab
Synonyms Click here for help
evinacumab-dgnb | Evkeeza® | REGN1500
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 529
Other databases
GtoPdb PubChem SID 252827375
Search PubMed clinical trials evinacumab
Search PubMed titles evinacumab
Search PubMed titles/abstracts evinacumab